Back to Journals » The Application of Clinical Genetics » Volume 13

Haptoglobin Gene Polymorphism in Patients with Sickle Cell Anemia: Findings from a Nigerian Cohort Study

Authors Olatunya OS, Albuquerque DM, Santos MNN, Kayode TS, Adekile A, Costa FF

Received 20 January 2020

Accepted for publication 26 March 2020

Published 8 May 2020 Volume 2020:13 Pages 107—114


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Martin H. Maurer

Oladele Simeon Olatunya,1,2 Dulcineia Martins Albuquerque,1 Magnun Nueldo Nunes Santos,3 Tolorunju Segun Kayode,4 Adekunle Adekile,5 Fernando Ferreira Costa1

1Hematology and Hemotherapy Center, University of Campinas, Campinas, São Paulo State, Brazil; 2Department of Paediatrics, College of Medicine, Ekiti State University, Ado Ekiti, Ekiti State, Nigeria; 3Department of Clinical Pathology, School of Medical Sciences, University of Campinas, Campinas, São Paulo State, Brazil; 4Department of Chemical Pathology, Ekiti State University Teaching Hospital, Ado Ekiti, Ekiti State, Nigeria; 5Department of Pediatrics, Faculty of Medicine, Kuwait University, Jabriya, Kuwait

Correspondence: Oladele Simeon Olatunya

Purpose: To determine the various haptoglobin genotypes and their influence on the clinico-laboratory manifestations among young Nigerian sickle cell anemia (SCA) patients.
Patients and Methods: A total of  101 SCA patients and 64 controls were studied. SCA was diagnosed by polymerase chain reaction (PCR). Haptoglobin genotype was determined by PCR followed by agarose gel electrophoresis. The patients’ laboratory and clinical parameters were differentiated by haptoglobin genotypes.
Results: The Hp1 and Hp2 alleles frequencies were 0.62 and 0.38 in the patients and 0.73 and 0.27 in the controls, respectively, and these did not differ significantly (p> 0.05). The haptoglobin genotype distribution among the patients and controls were Hp1-1, 43 (42.6%); Hp2-1, 40 (39.6%); Hp2-2, 18 (17.8%) and Hp1-1, 35 (54.7%); Hp2-1, 24 (37.5%); Hp2-2, 5 (7.8%), respectively, with no difference between the two groups (P> 0.05). No significant difference was found in the clinical events and laboratory parameters of the patients when partitioned according to the various haptoglobin genotypes (P> 0.05).
Conclusion: This study found that haptoglobin gene polymorphism does not have a significant influence on the clinico-laboratory manifestations among SCA patients.

Keywords: haptoglobin gene polymorphism, sickle cell disease, clinico-laboratory manifestations

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]